Serum and intratesticular inhibin B, AMH, and spermatogonial numbers in trans women at gender-confirming surgery: An observational study

被引:3
|
作者
Schneider, Florian [1 ,2 ]
Dabel, Jennifer [1 ]
Sandhowe-Klaverkamp, Reinhild [1 ]
Neuhaus, Nina [1 ]
Schlatt, Stefan [1 ]
Kliesch, Sabine [2 ]
Wistuba, Joachim [1 ]
机构
[1] Univ Hosp Muenster, Inst Reprod & Regenerat Med, Ctr Reprod Med & Androl, Munster, Germany
[2] Univ Hosp Muenster, Dept Clin & Surg Androl, Ctr Reprod Med & Androl, Munster, Germany
关键词
anti-Mullerian hormone; fertility preservation; gender-affirming hormone therapy; inhibin B; spermatogonia; trans women; ANTI-MULLERIAN HORMONE; TESTICULAR FUNCTION; DYSPHORIA; PUBERTY; VOLUME; CELLS; FSH;
D O I
10.1111/andr.13059
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Background Anti-Mullerian hormone and inhibin B are produced by Sertoli cells. Anti-Mullerian hormone secretion indicates an immature Sertoli cell state. Inhibin B serves as a marker of male fertility. Identification of markers reflecting the presence of germ cells is of particular relevance in trans persons undergoing gender-affirming hormone therapy in order to offer individualized fertility preservation methods. Objectives Serum and intratesticular inhibin B and anti-Mullerian hormone values were assessed and related to clinical features, laboratory values, and germ cell numbers. Materials and methods Twenty-two trans women from three clinics were included. As gender-affirming hormone therapy, 10-12.5 mg of cyproterone acetate plus estrogens were administered. Height, weight, age, medication, and treatment duration were inquired by questionnaires. Serum luteinizing hormone, follicle-stimulating hormone, testosterone, and estradiol were measured by immuno-assays. Serum and intratesticular inhibin B and anti-Mullerian hormone were measured by commercially available ELISAs. Spermatogonia were quantified as spermatogonia per cubic millimeter testicular tissue applying a morphometric analysis of two independent testicular cross-sections per individual after MAGEA4 immunostaining. Results Patients with high inhibin B levels presented with a higher number of spermatogonia (*p < 0.05). Furthermore, mean serum inhibin B was associated with low age (*p < 0.05), low follicle-stimulating hormone (*p < 0.05), and low testosterone (*p < 0.05). Serum anti-Mullerian hormone, however, was not related to spermatogonial numbers. It correlated with high testosterone (*p < 0.05) and high follicle-stimulating hormone (*p < 0.05) only. High intratesticular inhibin B was accompanied by high luteinizing hormone (*p < 0.05), high follicle-stimulating hormone (**p < 0.01), and high testosterone levels (**p < 0.01). Higher the intratesticular anti-Mullerian hormone levels, the longer gender-affirming hormone therapy was administered (*p < 0.05). Discussion and conclusion Serum inhibin B levels indicate the presence of spermatogonia, whereas anti-Mullerian hormone seems not to be a reliable marker concerning germ cell abundance.
引用
收藏
页码:1781 / 1789
页数:9
相关论文
共 3 条
  • [1] Effects of Gender-confirming Pitch-raising Surgery in Transgender Women a Long-term Follow-up Study of Acoustic and Patient-reported Data
    Kelly, Victoria
    Hertegard, Stellan
    Eriksson, Jenny
    Nygren, Ulrika
    Sodersten, Maria
    JOURNAL OF VOICE, 2019, 33 (05) : 781 - 791
  • [2] Study The Pharmacologic Effect Of Both Gonadotropins And Letrozole On The Level Of Serum Glycoproteins (Inhibin B, Amh, And Hrg) In Infertile Women And Their Effect On Stimulating Ovulation
    Abdulwahid, Hameedah Hadi
    AL-Saadi, Narjis Hadi
    Radhi, Inam Joudah
    Ai-Gazali, Rasha Qahtan
    Mankhi, Fattima Abdullah
    JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS, 2022, 13 : 299 - 303
  • [3] Study The Pharmacologic Effect Of Both Gonadotropins And Letrozole On The Level Of Serum Glycoproteins (Inhibin B, Amh, And Hrg) In Infertile Women And Their Effect On Stimulating Ovulation
    Abdulwahid, Hameedah Hadi
    AL-Saadi, Narjis Hadi
    Radhi, Inam Joudah
    Ai-Gazali, Rasha Qahtan
    Mankhi, Fattima Abdullah
    JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS, 2022, 13 : 299 - 303